BioCentury | Jun 4, 2012
Finance

Agendia's private party

...as to develop its pipeline. The company markets the Symphony suite of four tests - TargetPrint...
BioCentury | Jun 1, 2012
Financial News

Agendia raises $65 million

...see BioCentury, June 27, 2011) . Agendia markets the Symphony suite of four tests ( TargetPrint...
BioCentury | Jun 27, 2011
Finance

What to do with $101M

...diagnostics using tumor gene expression profiling. It markets the Symphony suite of four tests ( TargetPrint...
BioCentury | Jun 27, 2011
Finance

Off the agenda

...diagnostics using tumor gene expression profiling. It markets the Symphony suite of four tests ( TargetPrint...
BioCentury | Jun 13, 2011
Finance

Agendia's agenda

...diagnostics using tumor gene expression profiling. It markets the Symphony suite of four tests ( TargetPrint...
BioCentury | May 23, 2011
Finance

Euro IPOs

...diagnostics using tumor gene expression profiling. It markets the Symphony suite of four tests ( TargetPrint...
BioCentury | Mar 22, 2010
Product Development

Spies plot revolution

...In addition to standard ER and HER2 tests based on immunohistochemistry and FISH technology, Agendia's TargetPrint...
BioCentury | Mar 22, 2010
Clinical News

AMG 386: Trial started

...trial also will use Agendia's MammaPrint multi-gene expression test to determine eligibility and stratify patients; TargetPrint...
BioCentury | Mar 18, 2010
Clinical News

Adaptive breast cancer trial launched

...Netherlands), including MammaPrint multi-gene expression test to determine eligibility for the trial and stratify patients; TargetPrint...
BioCentury | Sep 8, 2008
Company News

Agendia sales and marketing update

...Agendia launched its TargetPrint breast cancer prognostic test in the U.S. to identify patients likely to...
Items per page:
1 - 10 of 10